Abstract
All type of implantations, especially for non-resorptive materials (metallic, hard insoluble polymers) involve an inflammatory response, followed by wound healing reaction (angiogenesis, fibroblast activation) and extracellular matrix (ECM) remodeling. An implanted biomaterial interacts not only with mobile cells of physiological body fluids but also with ECM. Almost all tissues (except epithelial tissues) possess an abundant ECM, with various compositions. Many implant failures may be due to an impaired cellular response (including inflammation) but all cell behavior can be influenced by the chemical composition and the physical properties of the ECM. Our group has performed various biomaterials testing in vivo by subcutaneous rat implantation followed by analysis of peri-implant tissues in order to detect inflammatory processes and their consequences.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abreu T, Silva G (2009) Cell movement: new research trends. Nova Biomedical Books, New York
Agren MS, Jorgensen LN, Andersen M, Viljanto J, Gottrup F (1998) Matrix metalloproteinase 9 level predicts optimal collagen deposition during early wound repair in humans. Br J Surg 85(1):68–71
Arumugam S, Jang YC, Chen-Jensen C, Gibran NS, Isik FF (1999) Temporal activity of plasminogen activators and matrix metalloproteinases during cutaneous wound repair. Surgery 125(6):587–593
Aschi M, Bozzi A, Di Bartolomeo R, Petruzzelli R (2010) The role of disulfide bonds and N-terminus in the structural properties of hepcidins: insights from molecular dynamics simulations. Biopolymers 93(10):917–926
Atassi F (2002) Periimplant probing: positives and negatives. Implant Dent 11(4):356–362
Baier RE, Meenaghan MA, Hartman LC, Wirth JE, Flynn HE, Meyer AE et al (1988) Implant surface characteristics and tissue interaction. J Oral Implantol 13(4):594–606
Banyai L, Tordai H, Patthy L (1994) The gelatin-binding site of human 72 kDa type IV collagenase (gelatinase A). Biochem J 298(Pt 2):403–407
Baramova E, Foidart JM (1995) Matrix metalloproteinase family. Cell Biol Int 19(3):239–242
Bernstein FC, Koetzle TF, Williams GJ, Meyer EF Jr, Brice MD, Rodgers JR et al (1978) The Protein Data Bank: a computer-based archival file for macromolecular structures. Arch Biochem Biophys 185(2):584–591
Bertini I, Calderone V, Fragai M, Luchinat C, Mangani S, Terni B (2004) Crystal structure of the catalytic domain of human matrix metalloproteinase 10. J Mol Biol 336(3):707–716
Betz M, Huxley P, Davies SJ, Mushtaq Y, Pieper M, Tschesche H et al (1997) 18-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur J Biochem 247(1):356–363
Bittar EE, Bittar N (1995) Cellular organelles and the extracellular matrix. JAI Press, Greenwich, CT
Black LD, Allen PG, Morris SM, Stone PJ, Suki B (2008) Mechanical and failure properties of extracellular matrix sheets as a function of structural protein composition. Biophys J 94(5):1916–1929
Blagg JA, Noe MC, Wolf-Gouveia LA, Reiter LA, Laird ER, Chang SP et al (2005) Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg Med Chem Lett 15(7):1807–1810
Bosman FT, Stamenkovic I (2003) Functional structure and composition of the extracellular matrix. J Pathol 200(4):423–428
Butler GS, Tam EM, Overall CM (2004) The canonical methionine 392 of matrix metalloproteinase 2 (gelatinase A) is not required for catalytic efficiency or structural integrity: probing the role of the methionine-turn in the metzincin metalloprotease superfamily. J Biol Chem 279(15):15615–15620
Carrascal N, Rizzo RC (2009) Calculation of binding free energies for non-zinc chelating pyrimidine dicarboxamide inhibitors with MMP-13. Bioorg Med Chem Lett 19(1):47–50
Chakrabarti B, Bairagya HR, Mallik P, Mukhopadhyay BP, Bera AK (2011) An insight to conserved water molecular dynamics of catalytic and structural Zn(+2) ions in matrix metalloproteinase 13 of human. J Biomol Struct Dyn 28(4):503–516
Clark IM, Young DA, Rowan AD (2010) Matrix metalloproteinase protocols, 2nd edn. Humana, New York, NY
Conant K, Gottschall PE (2005) Matrix metalloproteinases in the central nervous system. Imperial College Press, London, Hackensack, NJ, Distributed by World Scientific
Cornwell KG, Landsman A, James KS (2009) Extracellular matrix biomaterials for soft tissue repair. Clin Podiatr Med Surg 26(4):507–523
Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103(3):481–490
Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI (2004) Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 10(24):8229–8234
Curran S, Murray GI (1999) Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189(3):300–308
Damsky CH, Werb Z (1992) Signal transduction by integrin receptors for extracellular matrix: cooperative processing of extracellular information. Curr Opin Cell Biol 4(5):772–781
Diaz N, Suarez D (2007) Molecular dynamics simulations of matrix metalloproteinase 2: role of the structural metal ions. Biochemistry 46(31):8943–8952
Diaz N, Suarez D (2008) Molecular dynamics simulations of the active matrix metalloproteinase-2: positioning of the N-terminal fragment and binding of a small peptide substrate. Proteins 72(1):50–61
Eck SM, Hoopes PJ, Petrella BL, Coon CI, Brinckerhoff CE (2009) Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat 116(1):79–90
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161–174
El Haj AJ, Cartmell SH (2010) Bioreactors for bone tissue engineering. Proc Inst Mech Eng H 224(12):1523–1532
Ennis BW, Matrisian LM (1994) Matrix degrading metalloproteinases. J Neurooncol 18(2):105–109
Fainardi E, Castellazzi M, Tamborino C, Trentini A, Manfrinato MC, Baldi E et al (2009) Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis. Mult Scler 15(5):547–554
Freeman-Cook KD, Reiter LA, Noe MC, Antipas AS, Danley DE, Datta K et al (2007) Potent selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett 17(23):6529–6534
Gailit J, Clark RA (1994) Wound repair in the context of extracellular matrix. Curr Opin Cell Biol 6(5):717–725
Galvez BG, Genis L, Matias-Roman S, Oblander SA, Tryggvason K, Apte SS et al (2005) Membrane type 1-matrix metalloproteinase is regulated by chemokines monocyte-chemoattractant protein-1/ccl2 and interleukin-8/CXCL8 in endothelial cells during angiogenesis. J Biol Chem 280(2):1292–1298
Gapski R, Barr JL, Sarment DP, Layher MG, Socransky SS, Giannobile WV (2004) Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: a proof of concept trial. J Periodontol 75(3):441–452
Gapski R, Hasturk H, Van Dyke TE, Oringer RJ, Wang S, Braun TM et al (2009) Systemic MMP inhibition for periodontal wound repair: results of a multi-centre randomized-controlled clinical trial. J Clin Periodontol 36(2):149–156
Geisler S, Lichtinghagen R, Boker KH, Veh RW (1997) Differential distribution of five members of the matrix metalloproteinase family and one inhibitor (TIMP-1) in human liver and skin. Cell Tissue Res 289(1):173–183
Giaccone G, Soria J-C (2007) Targeted therapies in oncology. Informa Healthcare, New York
Goffin JR, Anderson IC, Supko JG, Eder JP Jr, Shapiro GI, Lynch TJ et al (2005) Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 11(9):3417–3424
Gramoun A, Goto T, Nordstrom T, Rotstein OD, Grinstein S, Heersche JN et al (2010) Bone matrix proteins and extracellular acidification: potential co-regulators of osteoclast morphology. J Cell Biochem 111(2):350–361
Grassi F, Cristino S, Toneguzzi S, Piacentini A, Facchini A, Lisignoli G (2004) CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol 199(2):244–251
Greenwald RA, Zucker S, Golub LM (1999) Inhibition of matrix metalloproteinases: therapeutic applications. New York Academy of Sciences, New York, NY
Gristina AG (1994) Implant failure and the immuno-incompetent fibro-inflammatory zone. Clin Orthop Relat Res (298):106–118
Gruber HE, Ingram JA, Hoelscher GL, Zinchenko N, Norton HJ, Hanley EN Jr (2009) Matrix metalloproteinase 28 a novel matrix metalloproteinase is constitutively expressed in human intervertebral disc tissue and is present in matrix of more degenerated discs. Arthritis Res Ther 11(6):R184
Gu Q, Wang D, Gao Y, Zhou J, Peng R, Cui Y et al (2002) Expression of MMP1 in surgical and radiation-impaired wound healing and its effects on the healing process. J Environ Pathol Toxicol Oncol 21(1):71–78
Hay ED (1991) Cell biology of extracellular matrix, 2nd edn. Plenum, New York
He H, Puerta DT, Cohen SM, Rodgers KR (2005) Structural and spectroscopic study of reactions between chelating zinc-binding groups and mimics of the matrix metalloproteinase and disintegrin metalloprotease catalytic sites: the coordination chemistry of metalloprotease inhibition. Inorg Chem 44(21):7431–7442
Hinds S, Bian W, Dennis RG, Bursac N (2011) The role of extracellular matrix composition in structure and function of bioengineered skeletal muscle. Biomaterials 32(14):3575–3583
Howard L, Zheng Y, Horrocks M, Maciewicz RA, Blobel C (2001) Catalytic activity of ADAM28. FEBS Lett 498(1):82–86
Van den Hu J, Steen PE, Houde M, Ilenchuk TT, Opdenakker G (2004) Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody. Biochem Pharmacol 67(5):1001–1009
Hubbell J (2006) Matrix-bound growth factors in tissue repair. Swiss Med Wkly 136(25–26): 387–391
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14(1):33–38, 27–38
Hyer S, Wei S, Brew K, Acharya KR (2007) Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1. J Biol Chem 282(1):364–371
Janusz MJ, Hookfin EB, Brown KK, Hsieh LC, Heitmeyer SA, Taiwo YO et al (2006) Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis. Inflamm Res 55(2):60–65
Jayakumar P, Di Silvio L (2010) Osteoblasts in bone tissue engineering. Proc Inst Mech Eng H 224(12):1415–1440
Jones KS (2008) Effects of biomaterial-induced inflammation on fibrosis and rejection. Semin Immunol 20(2):130–136
Juliano RL, Haskill S (1993) Signal transduction from the extracellular matrix. J Cell Biol 120(3):577–585
Karim RB, Brito BL, Dutrieux RP, Lassance FP, Hage JJ (2006) MMP-2 assessment as an indicator of wound healing: a feasibility study. Adv Skin Wound Care 19(6):324–327
Kass L, Erler JT, Dembo M, Weaver VM (2007) Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis. Int J Biochem Cell Biol 39(11):1987–1994
Kataoka H (2009) EGFR ligands and their signaling scissors ADAMs as new molecular targets for anticancer treatments. J Dermatol Sci 56(3):148–153
Khan OF, Jean-Francois J, Sefton MV (2010) MMP levels in the response to degradable implants in the presence of a hydroxamate-based matrix metalloproteinase sequestering biomaterial in vivo. J Biomed Mater Res A 93(4):1368–1379
Kimata M, Otani Y, Kubota T, Igarashi N, Yokoyama T, Wada N et al (2002) Matrix metalloproteinase inhibitor marimastat decreases peritoneal spread of gastric carcinoma in nude mice. Jpn J Cancer Res 93(7):834–841
Kinoshita T, Sato H, Okada A, Ohuchi E, Imai K, Okada Y et al (1998) TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 273(26):16098–16103
Kirkpatrick CJ, Krump-Konvalinkova V, Unger RE, Bittinger F, Otto M, Peters K (2002) Tissue response and biomaterial integration: the efficacy of in vitro methods. Biomol Eng 19(2–6):211–217
Koltsova EK, Ley K (2010) The mysterious ways of the chemokine CXCL5. Immunity 33(1):7–9
Kornberg L, Juliano RL (1992) Signal transduction from the extracellular matrix: the integrin-tyrosine kinase connection. Trends Pharmacol Sci 13(3):93–95
Krane SM (1995) Is collagenase (matrix metalloproteinase-1) necessary for bone and other connective tissue remodeling? Clin Orthop Relat Res (313):47–53
Kruger A, Soeltl R, Sopov I, Kopitz C, Arlt M, Magdolen V et al (2001) Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 61(4):1272–1275
Kurizaki T, Toi M, Tominaga T (1998) Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Rep 5(3):673–677
Lagente V, Boichot E (2008) Matrix metalloproteinases in tissue remodelling and inflammation. Birkhäuser, Basel; Boston
Lew DH, Yoon JH, Hong JW, Tark KC (2010) Efficacy of antiadhesion barrier solution on periimplant capsule formation in a white rat model. Ann Plast Surg 65(2):254–258
Li J, Zhang YP, Kirsner RS (2003) Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech 60(1):107–114
Madlener M, Parks WC, Werner S (1998) Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp Cell Res 242(1):201–210
Maller O, Martinson H, Schedin P (2010) Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland. J Mammary Gland Biol Neoplasia 15(3):301–318
Manuel JA, Gawronska-Kozak B (2006) Matrix metalloproteinase 9 (MMP-9) is upregulated during scarless wound healing in athymic nude mice. Matrix Biol 25(8):505–514
Matrisian LM, Wright J, Newell K, Witty JP (1994) Matrix-degrading metalloproteinases in tumor progression. Princess Takamatsu Symp 24:152–161
Metzmacher I, Ruth P, Abel M, Friess W (2007) In vitro binding of matrix metalloproteinase-2 (MMP-2) MMP-9 and bacterial collagenase on collagenous wound dressings. Wound Repair Regen 15(4):549–555
Morrison CJ, Overall CM (2006) TIMP independence of matrix metalloproteinase (MMP)-2 activation by membrane type 2 (MT2)-MMP is determined by contributions of both the MT2-MMP catalytic and hemopexin C domains. J Biol Chem 281(36):26528–26539
Muller M, Trocme C, Lardy B, Morel F, Halimi S, Benhamou PY (2008) Matrix metalloproteinases and diabetic foot ulcers: the ratio of MMP-1 to TIMP-1 is a predictor of wound healing. Diabet Med 25(4):419–426
Murshed M, McKee MD (2010) Molecular determinants of extracellular matrix mineralization in bone and blood vessels. Curr Opin Nephrol Hypertens 19(4):359–365
Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274(31):21491–21494
Nakamura Y, Sato K, Wakimoto N, Kimura F, Okuyama A, Motoyoshi K (2001) A new matrix metalloproteinase inhibitor SI-27 induces apoptosis in several human myeloid leukemia cell lines and enhances sensitivity to TNF alpha-induced apoptosis. Leukemia 15(8): 1217–1224
Neamtu M, Filioreanu AM, Petreus T, Badescu L, Ionescu CR, Cotrutz CE (2010) Involvement of MMP-8 in tissue response to colagenated fibrillar net in rats. Ann Roman Soc Cell Biol 15(1):236–241
Nilsen-Hamilton M, Werb Z, Keshet E (2003) Tissue remodeling. New York Academy of Sciences, New York, NY
Nomura H, Fujimoto N, Seiki M, Mai M, Okada Y (1996) Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer 69(1):9–16
Overall CM, Kleifeld O (2006) Tumour microenvironment—opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6(3):227–239
Parks WC, Mecham RP (1998) Matrix metalloproteinases. Academic, San Diego
Peled ZM, Phelps ED, Updike DL, Chang J, Krummel TM, Howard EW et al (2002) Matrix metalloproteinases and the ontogeny of scarless repair: the other side of the wound healing balance. Plast Reconstr Surg 110(3):801–811
Pepper MS (2001) Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21(7):1104–1117
Petreus T, Cotrutz CE, Neamtu M, Buruiana EC, Sirbu PD, Neamtu A (2010) Molecular docking on recomposed versus crystallographic structures of Zn-dependent enzymes and their natural inhibitors. Proc World Acad Sci Eng Technol 68:1992–1995
Petreus T, Cotrutz CE, Neamtu M, Buruiana EC, Sirbu PD, Neamtu A (2010) Understanding the dynamics–activity relationship in metalloproteases: ideas for new inhibition strategies. In: AT-EQUAL 2010: 2010 ECSIS Symposium on advanced technologies for enhanced quality of life: LAB-RS and ARTIPED 2010, pp 83–86
Ra HJ, Parks WC (2007) Control of matrix metalloproteinase catalytic activity. Matrix Biol 26(8):587–596
Rasmussen HS, McCann PP (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 75(1):69–75
Rayment EA, Upton Z, Shooter GK (2008) Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer. Br J Dermatol 158(5):951–961
Reijerkerk A, Kooij G, van der Pol SM, Khazen S, Dijkstra CD, de Vries HE (2006) Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells. FASEB J 20(14):2550–2552
Reiter LA, Freeman-Cook KD, Jones CS, Martinelli GJ, Antipas AS, Berliner MA et al (2006) Potent selective pyrimidinetrione-based inhibitors of MMP-13. Bioorg Med Chem Lett 16(22):5822–5826
Renault MA, Losordo DW (2007) The matrix revolutions: matrix metalloproteinase vasculogenesis and ischemic tissue repair. Circ Res 100(6):749–750
Rodriguez R, Loske AM, Fernandez F, Estevez M, Vargas S, Fernandez G et al (2010) In vivo evaluation of implant-host tissue interaction using morphology-controlled hydroxyapatite-based biomaterials. J Biomater Sci Polym Ed 22(13):1799–1810
Rosenblum G, Meroueh S, Toth M, Fisher JF, Fridman R, Mobashery S et al (2007) Molecular structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the cysteine switch dogma. J Am Chem Soc 129(44):13566–13574
Ruifrok AC, Katz RL, Johnston DA (2003) Comparison of quantification of histochemical staining by hue-saturation-intensity (HSI) transformation and color-deconvolution. Appl Immunohistochem Mol Morphol 11(1):85–91
Rush TS 3rd, Powers R (2004) The application of x-ray NMR and molecular modeling in the design of MMP inhibitors. Curr Top Med Chem 4(12):1311–1327
Salmela MT, Pender SL, Karjalainen-Lindsberg ML, Puolakkainen P, Macdonald TT, Saarialho-Kere U (2004) Collagenase-1 (MMP-1) matrilysin-1 (MMP-7) and stromelysin-2 (MMP-10) are expressed by migrating enterocytes during intestinal wound healing. Scand J Gastroenterol 39(11):1095–1104
Salonurmi T, Parikka M, Kontusaari S, Pirila E, Munaut C, Salo T et al (2004) Overexpression of TIMP-1 under the MMP-9 promoter interferes with wound healing in transgenic mice. Cell Tissue Res 315(1):27–37
Santos MA, Marques S, Gil M, Tegoni M, Scozzafava A, Supuran CT (2003) Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating succinyl hydroxamate and iminodiacetic acid hydroxamate moieties. J Enzyme Inhib Med Chem 18(3):233–242
Scatena R (2000) Prinomastat a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. Expert Opin Investig Drugs 9(9):2159–2165
Shekaran A, Garcia AJ (2011) Extracellular matrix-mimetic adhesive biomaterials for bone repair. J Biomed Mater Res A 96(1):261–272
Steward WP, Thomas AL (2000) Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs 9(12):2913–2922
Stratmann B, Farr M, Tschesche H (2001) MMP-TIMP interaction depends on residue 2 in TIMP-4. FEBS Lett 507(3):285–287
Sung HJ, Johnson CE, Lessner SM, Magid R, Drury DN, Galis ZS (2005) Matrix metalloproteinase 9 facilitates collagen remodeling and angiogenesis for vascular constructs. Tissue Eng 11(1–2):267–276
Takahashi H, Akiba K, Noguchi T, Ohmura T, Takahashi R, Ezure Y et al (2000) Matrix metalloproteinase activity is enhanced during corneal wound repair in high glucose condition. Curr Eye Res 21(2):608–615
Tang L, Eaton JW (1995) Inflammatory responses to biomaterials. Am J Clin Pathol 103(4):466–471
Tang L, Hu W (2005) Molecular determinants of biocompatibility. Expert Rev Med Devices 2(4):493–500
Tanner KE (2010) Bioactive composites for bone tissue engineering. Proc Inst Mech Eng H 224(12):1359–1372
Terasaki K, Kanzaki T, Aoki T, Iwata K, Saiki I (2003) Effects of recombinant human tissue inhibitor of metalloproteinases-2 (rh-TIMP-2) on migration of epidermal keratinocytes in vitro and wound healing in vivo. J Dermatol 30(3):165–172
Thevenot P, Hu W, Tang L (2008) Surface chemistry influences implant biocompatibility. Curr Top Med Chem 8(4):270–280
Underwood CK, Min D, Lyons JG, Hambley TW (2003) The interaction of metal ions and Marimastat with matrix metalloproteinase 9. J Inorg Biochem 95(2–3):165–170
Vaalamo M, Leivo T, Saarialho-Kere U (1999) Differential expression of tissue inhibitors of metalloproteinases (TIMP-1 -2 -3 and -4) in normal and aberrant wound healing. Hum Pathol 30(7):795–802
Velasco G, Pendas AM, Fueyo A, Knauper V, Murphy G, Lopez-Otin C (1999) Cloning and characterization of human MMP-23 a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J Biol Chem 274(8):4570–4576
Willenbrock F, Murphy G, Phillips IR, Brocklehurst K (1995) The second zinc atom in the matrix metalloproteinase catalytic domain is absent in the full-length enzymes: a possible role for the C-terminal domain. FEBS Lett 358(2):189–192
Woessner JF Jr (1994) The family of matrix metalloproteinases. Ann N Y Acad Sci 732:11–21
Woessner JF Jr (2001) That impish TIMP: the tissue inhibitor of metalloproteinases-3. J Clin Invest 108(6):799–800
Wolber G, Langer T (2005) LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 45(1):160–169
Wolber G, Seidel T, Bendix F, Langer T (2008) Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discov Today 13(1–2):23–29
Zhang W, Hou TJ, Qiao XB, Huai S, Xu XJ (2004) Binding affinity of hydroxamate inhibitors of matrix metalloproteinase-2. J Mol Model 10(2):112–120
Zohny SF, Fayed ST (2010) Clinical utility of circulating matrix metalloproteinase-7 (MMP-7) CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol 27(4):1246–1253
Zucker S, Drews M, Conner C, Foda HD, DeClerck YA, Langley KE et al (1998) Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 273(2):1216–1222
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Petreus, T., Antoniac, I., Sirbu, P., Cotrutz, C.E. (2013). Molecular Scissors: From Biomaterials Implant to Tissue Remodeling. In: Antoniac, I. (eds) Biologically Responsive Biomaterials for Tissue Engineering. Springer Series in Biomaterials Science and Engineering, vol 1. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4328-5_2
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4328-5_2
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4327-8
Online ISBN: 978-1-4614-4328-5
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)